Short answer:
Yes—side effects from Keytruda (pembrolizumab) can change and sometimes worsen as treatment continues. They can appear early, late, or even after a break in therapy.
---
How Keytruda works and why the timing of side effects matters
Keytruda is an immune‑checkpoint inhibitor. It lifts the “brakes” on your immune system so it can attack cancer cells. Because it ramps up immune activity, the drug can trigger a range of immune‑related adverse events (irAEs) that can affect many organs—skin, gut, liver, endocrine glands, lungs, and more.
- Early‑onset irAEs (within the first few weeks) often include rash, diarrhea/colitis, thyroiditis, and fatigue.
- Late‑onset irAEs can develop months after starting therapy, even if earlier doses were well tolerated. Examples are pneumonitis, hepatitis, or endocrine dysfunction that may persist or worsen over time.
- Cumulative toxicity: Repeated exposure can lead to gradual worsening of symptoms (e.g., progressive fatigue or worsening liver enzyme elevations).
---
Common side‑effect trajectories
| Side effect | Typical onset | Possible evolution |
|-------------|---------------|-------------------|
| Fatigue | Early | May persist or increase with continued dosing; sometimes improves after treatment stops. |
| Nausea/vomiting | Early | Can subside with anti‑emetics but may recur or worsen if dose increases. |
| Rash / pruritus | Early | Can flare with continued therapy; sometimes resolves on its own or requires steroids. |
| Colitis / diarrhea | Early to late | Can become more severe; may require high‑dose steroids or immunosuppressants. |
| Endocrine problems (e.g., hypothyroidism, adrenal insufficiency) | Late | Often irreversible; requires lifelong hormone replacement. |
| Pneumonitis | Late | May be subtle initially; can progress quickly if not treated. |
| Hepatitis | Late | Liver enzymes can rise progressively; monitoring is essential. |
| Neurological symptoms (e.g., neuropathy, myasthenia gravis) | Late | Can develop months after therapy initiation. |
---
Why some side effects “worsen” over time
1. Cumulative immune activation – each infusion can further prime the immune system, making irAEs more likely or intense.
2. Organ tolerance limits – some tissues (e.g., adrenal glands) are more vulnerable to damage over time.
3. Delayed immune responses – the immune system may take weeks–months to mount a response that manifests clinically.
4. Patient factors – age, pre‑existing autoimmune disease, concurrent medications, or comorbidities can influence how side effects evolve.
---
Managing worsening side effects
| Step | What to do | Why it matters |
|------|------------|----------------|
| Regular monitoring | Labs (CBC, LFTs, thyroid panel, cortisol) every 3–6 weeks | Catch rising enzyme levels or hormonal changes early. |
| Prompt symptom reporting | Tell your oncologist right away if you notice new or worsening symptoms | Early intervention can prevent severe complications. |
| Steroid taper | High‑dose steroids for severe irAEs, then gradual taper | Reduces immune activity while protecting the organ. |
| Immunosuppressants | Mycophenolate, infliximab, or other agents if steroids fail | Target specific organ inflammation. |
| Hold or discontinue Keytruda | If irAEs are grade 3 or higher, treatment may be paused or stopped | Prevents irreversible damage. |
| Hormone replacement | Lifelong levothyroxine, hydrocortisone, or estrogen/progesterone as needed | Maintains endocrine function. |
---
Bottom line
- Side effects can appear at any time during Keytruda therapy—early or late.
- They can worsen or evolve as treatment continues, especially for immune‑related toxicities.
- Regular follow‑up and early reporting of symptoms are key to catching and treating worsening side effects before they become severe.
If you’re currently on Keytruda and notice new or worsening symptoms, reach out to your oncology team immediately. They’ll decide on the best strategy—adjusting the dose, adding steroids, or temporarily stopping the drug—to keep you safe and comfortable.